MEIP
Companies
NASDAQ
Mei Pharma Inc.
Health Care
$2.25
-$0.23 (-9.35%)
Price Chart
Overview
About MEIP
mei pharma (nasdaq: meip) is a san diego-based oncology company focused on the clinical development of novel therapies for cancer. our lead drug candidate is pracinostat, a potential best-in-class, oral hdac inhibitor that has been granted breakthrough therapy designation from the fda in combination with azacitidine for the treatment of patients with newly diagnosed aml who are ≥75 years of age or unfit for intensive chemotherapy. our pipeline of drug candidates also includes me-401 (formerly pwt143), a next-generation oral pi3k delta inhibitor, and me-344, a novel mitochondrial inhibitor. for more, please go to www.meipharma.com.
Market Cap
$19.1M
Volume
24.0K
Avg. Volume
21.2K
P/E Ratio
-0.53636116
Dividend Yield
0.00%
Employees
86.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.48
Low Correlation
Volatility
High (0.46)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Low Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, MEIP shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$19.1M
Volume24.0K
P/E Ratio-0.54
Dividend Yield0.00%
Important Dates
Next Dividend
December 6, 2023Next Earnings
February 13, 2025Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025